Abstract
Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Current Signal Transduction Therapy
Title:Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Volume: 8 Issue: 2
Author(s): Camila Chaves Santos, Rodrigo Chaves, Ana Cristina Borges, Michelle Oliveira de Castro and Helio Miranda Costa-Junior
Affiliation:
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Abstract: Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Export Options
About this article
Cite this article as:
Santos Chaves Camila, Chaves Rodrigo, Borges Cristina Ana, de Castro Oliveira Michelle and Costa-Junior Miranda Helio, Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660007
DOI https://dx.doi.org/10.2174/15743624113086660007 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus
Current Diabetes Reviews New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
Current Cardiology Reviews Transient Tachypnea of the Newborn: The Treatment Strategies
Current Pharmaceutical Design Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Nopal (Opuntia spp.) and its Effects on Metabolic Syndrome: New Insights for the Use of a Millenary Plant
Current Pharmaceutical Design Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design An Up-to-Date Review on Citrus Flavonoids: Chemistry and Benefits in Health and Diseases
Current Pharmaceutical Design Pharmacology and Perioperative Considerations for Diabetes Mellitus Medications
Current Clinical Pharmacology Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry The Prototype of Glycogen Phosphorylase
Mini-Reviews in Medicinal Chemistry Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews